Here is an enlightening article about patent expirations in India; those in the know can correct if there are errors in the piece: Lihavuuslääkkeen h-hetki perjantaina – voi puolittaa hinnan - Ilta-Sanomat
7 Likes
The article below doesn’t really concern Novo as an investment, but I thought it might still be of interest in this thread. 
The article tells how GLP-1 drugs developed by Eli Lilly and Novo Nordisk are changing the food markets so much that food giants have to adapt to people’s new eating habits caused by these drugs.
The success of pharmaceutical companies forces businesses to emphasize protein and smaller portion sizes, as consumers’ hunger and snacking decrease. In the future, more pill-form medications could further expand the user base, making pharmaceutical giants indirect trendsetters for the entire global restaurant industry and trade.
Key Points
- For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses.
- About one in every eight U.S. adults is currently taking a GLP-1 drug, like Ozempic or Zepbound, according to the KFF Health Tracking Poll.
- About 70% of GLP-1 users who report consuming fewer calories said that they are snacking less, according to a survey conducted by EY-Parthenon last spring.
https://www.cnbc.com/2026/03/21/glp-1-diets-restaurants-protein-fiber-weight-loss-drugs.html
10 Likes
Quite a short article, with a few interesting highlights below. A study with nearly 100,000 participants over a 13-year follow-up period.
The use of diabetes and weight loss medications significantly alleviated patients’ mental health problems in a recent international study.
The effect was most pronounced in patients who used semaglutide, i.e., the weight loss drugs Ozempic or Rybelsus. The study dispels previous fears that these medications would increase suicidal thoughts.
According to the study, the number of sick leaves decreased by 47 percent. More than 800 million people worldwide suffer from type 2 diabetes, and they have twice the risk of depression compared to the general population.
…
Could diabetes or weight loss medications be beneficial for those who suffer from depression but are not overweight? Research director Markku Lähteenvuo from the University of Eastern Finland considers it possible.
…
The study involved nearly 100,000 individuals, of whom over 20,000 had used GLP-1 medications. These include diabetes and weight loss drugs. Participants were followed using Swedish national registers between 2009 and 2022.
14 Likes
https://www.bizjournals.com/triangle/news/2026/03/24/novo-nordisk-wegovy-hd-fda-approval.html
High-dose Wegovy gets the green light from the FDA. 
This was old news anyway, and people are pretty tired of owning this stock 
- but I’ll post it regardless.
9 Likes